Login to Your Account

Financings Roundup

Momenta Seeks to Raise $57M to Fund Follow-on Biologics

By Marie Powers

Thursday, December 9, 2010
Just one day after filing a prospectus with the SEC for a registered underwritten public offering, Momenta Pharmaceuticals Inc. has priced the offering of 4 million shares of its common stock (NASDAQ:MNTA) at $14.35 per share. The proceeds, before expenses, to Momenta will be approximately $57.4 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription